inclusion criteria: 1. adult male or female aged 19 to 55 years at the screening visit (visit 1) 2. subject with a body mass index (bmi) of 18kg/m2 or more and 30kg/m2 or less at the screening visit (visit 1) 3. women of childbearing potential who have not undergone sterilization must agree to use an appropriate method of contraception\* during this clinical trial period and up to 3 months after the end of administration of the investigational drug and there must be evidence of non-fertility at the screening visit (visit 1) 4. men who has not undergone a vasectomy must consent to the use of barrier contraception (i.e., condoms) and if both subejct and partner agree to use an appropriate method of contraception for the duration of the clinical trial and up to 6 months after the end of investigational drug administration 5. subject who can collect blood and urine during this clinical trial period including the last visit 6. subject who havs heard the detailed explanation of this clinical trial, have voluntarily decided to participate, and have agreed in writing to abide by the precautions 7. subject who agrees not to donate blood or transfusion (including whole blood, plasma components, platelet components and platelet plasma components) during the clinical trial period

inclusion criteria: 1. adult male or female aged 19 to 55 years at the screening visit (visit 1) 2. subject with a body mass index (bmi) of 18kg/m2 or more and 30kg/m2 or less at the screening visit (visit 1) 3. women of childbearing potential who have not undergone sterilization must agree to use an appropriate method of contraception\* during this clinical trial period and up to 3 months after the end of administration of the investigational drug and there must be evidence of non-fertility at the screening visit (visit 1) 4. men who has not undergone a vasectomy must consent to the use of barrier contraception (i.e., condoms) and if both subejct and partner agree to use an appropriate method of contraception for the duration of the clinical trial and up to 6 months after the end of investigational drug administration 5. subject who can collect blood and urine during this clinical trial period including the last visit 6. subject who havs heard the detailed explanation of this clinical trial, have voluntarily decided to participate, and have agreed in writing to abide by the precautions 7. subject who agrees not to donate blood or transfusion (including whole blood, plasma components, platelet components and platelet plasma components) during the clinical trial period

inclusion criteria: adult male or female aged 19 to 55 years at the screening visit (visit 1) subject with a body mass index (bmi) of 18kg/m2 or more and 30kg/m2 or less at the screening visit (visit 1) women of childbearing potential who have not undergone sterilization must agree to use an appropriate method of contraception* during this clinical trial period and up to 3 months after the end of administration of the investigational drug and there must be evidence of non-fertility at the screening visit (visit 1) men who has not undergone a vasectomy must consent to the use of barrier contraception (i.e., condoms) and if both subejct and partner agree to use an appropriate method of contraception for the duration of the clinical trial and up to 6 months after the end of investigational drug administration subject who can collect blood and urine during this clinical trial period including the last visit subject who havs heard the detailed explanation of this clinical trial, have voluntarily decided to participate, and have agreed in writing to abide by the precautions subject who agrees not to donate blood or transfusion (including whole blood, plasma components, platelet components and platelet plasma components) during the clinical trial period

inclusion criteria: adult male or female aged 19 to 55 years at the screening visit (visit 1) subject with a body mass index (bmi) of 18kg/m2 or more and 30kg/m2 or less at the screening visit (visit 1) women of childbearing potential who have not undergone sterilization must agree to use an appropriate method of contraception* during this clinical trial period and up to 3 months after the end of administration of the investigational drug and there must be evidence of non-fertility at the screening visit (visit 1) men who has not undergone a vasectomy must consent to the use of barrier contraception (i.e., condoms) and if both subejct and partner agree to use an appropriate method of contraception for the duration of the clinical trial and up to 6 months after the end of investigational drug administration subject who can collect blood and urine during this clinical trial period including the last visit subject who havs heard the detailed explanation of this clinical trial, have voluntarily decided to participate, and have agreed in writing to abide by the precautions subject who agrees not to donate blood or transfusion (including whole blood, plasma components, platelet components and platelet plasma components) during the clinical trial period